At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 90 target
Drug / intervention
ZG005 for Injection +3 morebiological
Likely dose
ZG005 for Injection 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating ZG005 for Injection, Bevacizumab, and 1 other intervention for Hepatocellular Carcinoma. Currently recruiting, targeting 90 participants across 1 site.
Detailed Summary
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20252026
First PostedAug 2024
Enrollment StartOct 2024
TodayJul 2026
Primary CompletionSep 2026
Study CompletionOct 2026
First PostedAug 16, 2024
Enrollment StartOct 24, 2024
Primary CompletionSep 1, 2026
Study CompletionOct 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.9 years agoPrimary completion in 2 months
Interventions
ZG005 for Injectionbiological
10 mg/kg or 20 mg/kg administered intravenously Q3w
Bevacizumabbiological
15 mg/kg administered intravenously Q3w
Sintilimabbiological
200 mg administered intravenously Q3w
Bevacizumabbiological
15 mg/kg administered intravenously Q3w